128 related articles for article (PubMed ID: 6633616)
21. Longitudinal microradioscopic comparisons on endosteal and juxtaendosteal bone loss in premenopausal and postmenopausal women, and in those with end-stage renal disease.
Meema HE; Meema S
Bone; 1987; 8(6):343-50. PubMed ID: 3449109
[TBL] [Abstract][Full Text] [Related]
22. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat.
Sibonga JD; Lotinun S; Evans GL; Pribluda VS; Green SJ; Turner RT
Endocrinology; 2003 Mar; 144(3):785-92. PubMed ID: 12586754
[TBL] [Abstract][Full Text] [Related]
23. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Spona J; Huber J; Schmidt JB
Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
[TBL] [Abstract][Full Text] [Related]
24. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats.
Fanti P; Monier-Faugere MC; Geng Z; Schmidt J; Morris PE; Cohen D; Malluche HH
Osteoporos Int; 1998; 8(3):274-81. PubMed ID: 9797913
[TBL] [Abstract][Full Text] [Related]
25. Rationale for use of lower estrogen doses for postmenopausal hormone therapy.
Ettinger B
Maturitas; 2007 May; 57(1):81-4. PubMed ID: 17383126
[TBL] [Abstract][Full Text] [Related]
26. Clinical Review: Sex steroids and the periosteum--reconsidering the roles of androgens and estrogens in periosteal expansion.
Vanderschueren D; Venken K; Ophoff J; Bouillon R; Boonen S
J Clin Endocrinol Metab; 2006 Feb; 91(2):378-82. PubMed ID: 16303833
[TBL] [Abstract][Full Text] [Related]
27. High-dose gestagens modulate bone resorption and formation and enhance estrogen-induced endosteal bone formation in the ovariectomized mouse.
Bain SD; Jensen E; Celino DL; Bailey MC; Lantry MM; Edwards MW
J Bone Miner Res; 1993 Feb; 8(2):219-30. PubMed ID: 8442440
[TBL] [Abstract][Full Text] [Related]
28. The amount of periosteal apposition required to maintain bone strength during aging depends on adult bone morphology and tissue-modulus degradation rate.
Jepsen KJ; Andarawis-Puri N
J Bone Miner Res; 2012 Sep; 27(9):1916-26. PubMed ID: 22532507
[TBL] [Abstract][Full Text] [Related]
29. Regional adipose tissue metabolism in postmenopausal women after treatment with exogenous sex steroids.
Lindberg UB; Crona N; Silfverstolpe G; Björntorp P; Rebuffé-Scrive M
Horm Metab Res; 1990 Jun; 22(6):345-51. PubMed ID: 2116375
[TBL] [Abstract][Full Text] [Related]
30. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
31. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
Weissberger AJ; Ho KK; Lazarus L
J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
[TBL] [Abstract][Full Text] [Related]
32. PGE2 stimulates both resorption and formation of bone in vitro: differential responses of the periosteum and the endosteum in fetal rat long bone cultures.
Nefussi JR; Baron R
Anat Rec; 1985 Jan; 211(1):9-16. PubMed ID: 3985383
[TBL] [Abstract][Full Text] [Related]
33. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study.
Ausmanas MK; Holinka CF; Ling YS; Christiansen C
Climacteric; 2007 Aug; 10(4):306-13. PubMed ID: 17653957
[TBL] [Abstract][Full Text] [Related]
34. 17 beta-estradiol stimulates cancellous bone formation in female rats.
Chow JW; Lean JM; Chambers TJ
Endocrinology; 1992 May; 130(5):3025-32. PubMed ID: 1572310
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the relative rates of bone mineral content loss in postmenopause due to both estrogen deficiency and ageing.
Gnudi S; Mongiorgi R; Figus E; Bertocchi G
Boll Soc Ital Biol Sper; 1990 Dec; 66(12):1153-9. PubMed ID: 2100526
[TBL] [Abstract][Full Text] [Related]
36. [Sex hormone replacement following menopause--for all women? A plea for prevention using estrogens and gestagens].
Nocke W
Ther Umsch; 1995 Oct; 52(10):693-704. PubMed ID: 7482382
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII.
Gordon EM; Williams SR; Frenchek B; Mazur CA; Speroff L
J Lab Clin Med; 1988 Jan; 111(1):52-6. PubMed ID: 3335825
[TBL] [Abstract][Full Text] [Related]
38. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
[TBL] [Abstract][Full Text] [Related]
39. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
40. Radiogrammetry at four bone sites in normal middle-aged women. their relation to each other, to calcium metabolism and to other biological variables.
Saville PD; Heaney RP; Recker RR
Clin Orthop Relat Res; 1976; (114):307-15. PubMed ID: 1261127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
